Gene therapy with stem cells for early type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests an experimental gene therapy using your own stem cells to treat early type 1 diabetes. It aims to preserve insulin-making cells and potentially reduce your need for insulin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 40 years old
- You were diagnosed with type 1 diabetes within the last 6 months
- You have been on insulin for less than 180 days
- Your HbA1c is between 53 and 150 mmol/mol
- You test positive for at least 2 diabetes autoantibodies
- Your C-peptide (a measure of insulin production) is not too low
- Your body mass index (BMI) is 27 or lower
- You have not had a diabetes-related emergency in the past 2 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational gene therapy that may help people with type 1 diabetes produce some insulin on their own, potentially reducing the amount of insulin they need. It is an early-stage study, so participants will be closely monitored for safety and any changes in their diabetes control.
This study tests a new gene therapy (VV-14300) that aims to help people with type 1 diabetes make insulin again. It might improve blood sugar control and reduce the need for insulin.
This study tests a treatment that uses a patient's own immune cells to help the body make more insulin. It may help people with type 1 diabetes manage their blood sugar better.
This trial tests whether giving your own regulatory T cells (a type of immune cell) back to you can help slow or stop the immune attack on your pancreas in type 1 diabetes. It is for people aged 8 to 65 who still make some insulin.
This trial tests a new treatment made from stem cells that may help people with diabetes who have dangerous low blood sugar episodes. It aims to see if these cells can replace some of the pancreas function and prevent severe hypoglycemia.
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to stop the body's immune system from attacking insulin-producing cells in type 1 diabetes. The goal is to help preserve remaining pancreas function in people with early-stage disease.
Hear when a new Diabetes, Type I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.